Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02301624 · ClinicalTrials.gov registry record · Phase 3
Extension Study of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis
A Phase 3 study, sponsored by Alexion Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 117
- Enrollment target
NCT02301624 is a Phase 3 study that has completed, run by Alexion Pharmaceuticals. The registered enrollment target is 117 participants.
The verdict
NCT02301624, a Phase 3 study, has completed, sponsored by Alexion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 117 participants
- Enrollment target
Study Summary
To evaluate the safety and efficacy of eculizumab in the treatment of refractory generalized myasthenia gravis (gMG) as an extension study for the participants who previously completed Study ECU-MG-301(NCT01997229).
Interventions
- DRUG Placebo
- BIOLOGICAL Eculizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2014-11-12 |
| Est. Completion | 2019-01-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02301624
The ClinicalTrials.gov registry entry for NCT02301624 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 117 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02301624 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02301624 about?
NCT02301624 is a clinical study titled "Extension Study of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis". To evaluate the safety and efficacy of eculizumab in the treatment of refractory generalized myasthenia gravis (gMG) as an extension study for the participants who previously completed Study ECU-MG-301(NCT01997229).
What is the current status of trial NCT02301624?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 117 participants. The study started on 2014-11-12. Estimated completion is 2019-01-15.
What interventions are being tested in trial NCT02301624?
The interventions under investigation include: Placebo (DRUG), Eculizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02301624?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.